RECK is not an independent prognostic marker for breast cancer

BMC Cancer

Table 3 Cox regression for disease-free survival analysis in the entire patient cohort

	Entire cohort (n = 940)
	Univariate			Multivariate^a
Prognostic factor	HR	95 % CI	p-value	HR	95 % CI	p-value
RECK (low vs. high)	0.98	0.69-1.38	0.89	0.95	0.64–1.31	0.63
Age (continuous)	1.01	1.00–1.01	<0.01	1.01	1.00–1.02	<0.01
Tumor size (continuous)	1.08	1.06–1.11	<0.01	1.06	1.03–1.09	<0.01
Histological grading (3 vs. 1–2)	1.28	1.16–1.42	<0.01	1.26	1.13–1.41	<0.01
TNM stage (IV vs. I–III)	1.13	1.05–1.22	<0.01	1.07	0.99–1.14	0.08
Nodal status (positive vs. negative)	1.57	1.37–1.80	<0.01	1.51	1.31–1.74	<0.01
ER (positive vs. negative)	0.89	0.78–1.02	0.11	1.04	0.87–1.23	0.68
PR (positive vs. negative)	0.85	0.75–0.97	0.01	0.92	0.79–1.08	0.3
Her2 (positive vs. negative)	1.16	0.96–1.40	0.13	0.96	0.78–1.18	0.71

RECK. REversion-inducing Cysteine-rich protein with Kazal motifs; ER. estrogen receptor; PR. progesterone receptor; Her2. human epidermal growth factor 2
^aAdjusted for all other variables in the table

ISSN: 1471-2407